Novo-Nordisk A/S

US · NVO #73 by market cap Listed 1970 AI Rating C 68

46.60 -0.91 -1.92%

Collector offline (last heartbeat: 15855s ago) · 2026-09-04 20:02

Pre-market 46.36 -2.42%

After-hours 46.50 -0.21%

Overnight 46.81 -1.47%

Mkt cap: 208.07B
P/E (TTM): 11.44
P/B: 6.05
EPS: 3.58
Div yield: 3.83%
52W pos: 46%

About Novo-Nordisk A/S

Novo Nordisk is a Danish pharmaceutical company built around diabetes and obesity care — including cardiovascular and emerging related therapies — alongside a rare-disease unit covering blood disorders and hormone-replacement treatments. Harald and Thorvald Pedersen founded the company in 1923; it is headquartered in Bagsvaerd, Denmark.

Founded: 1923
CEO: Mr. Maziar Mike Doustdar
Employees: 69,505
Headquarters: Bagsv?rd, Capital Region, Denmark
Fiscal year end: 12-31
Website: novonordisk.com

View SEC filings on EDGAR ›

Company profile

Exchange: US
Symbol: NVO
Market-cap rank: #73
Listing date: 1970-01-01
Market cap: 208.07B
Float cap: 148.65B
Shares out: 4.47B
Float shares: 3.19B

Sectors & themes

Drug Manufacturers - General Weight Loss Drugs Fractional Shares JP

Browse all sectors & themes